Geron (NASDAQ:GERN) Trading 6.3% Higher

Share on StockTwits

Geron Co. (NASDAQ:GERN) traded up 6.3% during trading on Friday . The company traded as high as $1.55 and last traded at $1.53, 2,261,000 shares were traded during mid-day trading. An increase of 0% from the average session volume of 2,260,143 shares. The stock had previously closed at $1.44.

A number of equities research analysts have recently commented on the company. ValuEngine raised Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. B. Riley increased their target price on Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a research note on Friday, June 28th. HC Wainwright assumed coverage on Geron in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $4.00 target price on the stock. BidaskClub cut Geron from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. Finally, Cantor Fitzgerald assumed coverage on Geron in a research note on Thursday, August 15th. They issued an “overweight” rating and a $4.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.90.

The stock has a market capitalization of $271.33 million, a PE ratio of -9.56 and a beta of 2.51. The business has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.50.

Geron (NASDAQ:GERN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Geron had a negative return on equity of 22.33% and a negative net margin of 5,328.80%. The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, sell-side analysts expect that Geron Co. will post -0.43 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in GERN. Virtus ETF Advisers LLC purchased a new stake in shares of Geron during the second quarter valued at $252,000. Vanguard Group Inc. boosted its position in shares of Geron by 1.5% during the second quarter. Vanguard Group Inc. now owns 9,644,900 shares of the biopharmaceutical company’s stock valued at $13,599,000 after buying an additional 141,384 shares during the last quarter. Creative Planning purchased a new stake in shares of Geron during the second quarter valued at $168,000. MetLife Investment Advisors LLC purchased a new stake in shares of Geron during the first quarter valued at $150,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Geron by 11.0% during the second quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 79,827 shares during the last quarter. 31.16% of the stock is currently owned by institutional investors.

About Geron (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Article: Understanding each part of a balance sheet

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Maverix Metals  PT Lowered to C$7.75
Maverix Metals PT Lowered to C$7.75
Stroeer SE & Co KGaA  Given a €80.00 Price Target by Hauck & Aufhaeuser Analysts
Stroeer SE & Co KGaA Given a €80.00 Price Target by Hauck & Aufhaeuser Analysts
Bilfinger  Given a €34.00 Price Target by Independent Research Analysts
Bilfinger Given a €34.00 Price Target by Independent Research Analysts
Tesco  Earns News Impact Score of 4.00
Tesco Earns News Impact Score of 4.00
FY2019 Earnings Forecast for Millendo Therapeutics Inc Issued By Oppenheimer
FY2019 Earnings Forecast for Millendo Therapeutics Inc Issued By Oppenheimer
Imperial Capital Weighs in on Northern Oil & Gas, Inc.’s FY2019 Earnings
Imperial Capital Weighs in on Northern Oil & Gas, Inc.’s FY2019 Earnings


© 2006-2019 Ticker Report